Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (171-180 of 315) with videos related to

Pageof 32
Sort By:
The British Journal of Dermatology|April 9, 2024
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis controlEric L Simpson, Laurent Eckert, Abhijit Gadkari, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Current Medical Research and Opinion|November 29, 2019
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)David M Pariser, Eric L Simpson, Abhijit Gadkari, et al.
JAMA Dermatology|April 15, 2026
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus StatementJoseph F Merola, Beth A Childs, Brooke R Bartley, et al.
JAAD International|March 28, 2024
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Angel Cronin, Eric A Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 2, 2009
Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infection among Satowanese islandersJoseph V Lillis, Vernon E Ansdell, Kino Ruben, et al.
Journal of the American Academy of Dermatology|June 9, 2016
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Eric L Simpson, Abhijit Gadkari, Margitta Worm, et al.
Pediatrics|August 5, 2015
Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care ProvidersLawrence F Eichenfield, Mark Boguniewicz, Eric L Simpson, et al.
The British Journal of Dermatology|December 10, 2024
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Anthony Bewley, H Chih-Ho Hong, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 2, 2019
Conceptual Model to Illustrate the Symptom Experience and Humanistic Burden Associated With Atopic Dermatitis in Adults and AdolescentsLaura Grant, Lotte Seiding Larsen, Claire Trennery, et al.
Pageof 32

Showing results (171-180 of 315) with videos related to

Sort By:
Pageof 32
The British Journal of Dermatology|April 9, 2024
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis controlEric L Simpson, Laurent Eckert, Abhijit Gadkari, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Current Medical Research and Opinion|November 29, 2019
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)David M Pariser, Eric L Simpson, Abhijit Gadkari, et al.
JAMA Dermatology|April 15, 2026
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus StatementJoseph F Merola, Beth A Childs, Brooke R Bartley, et al.
JAAD International|March 28, 2024
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Angel Cronin, Eric A Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 2, 2009
Sequelae of World War II: an outbreak of chronic cutaneous nontuberculous mycobacterial infection among Satowanese islandersJoseph V Lillis, Vernon E Ansdell, Kino Ruben, et al.
Journal of the American Academy of Dermatology|June 9, 2016
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Eric L Simpson, Abhijit Gadkari, Margitta Worm, et al.
Pediatrics|August 5, 2015
Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care ProvidersLawrence F Eichenfield, Mark Boguniewicz, Eric L Simpson, et al.
The British Journal of Dermatology|December 10, 2024
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitisStephan Weidinger, Anthony Bewley, H Chih-Ho Hong, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 2, 2019
Conceptual Model to Illustrate the Symptom Experience and Humanistic Burden Associated With Atopic Dermatitis in Adults and AdolescentsLaura Grant, Lotte Seiding Larsen, Claire Trennery, et al.
Pageof 32